WO1998025886A1 - Novel compounds useful as therapeutic agents and assay reagents - Google Patents

Novel compounds useful as therapeutic agents and assay reagents Download PDF

Info

Publication number
WO1998025886A1
WO1998025886A1 PCT/GB1997/003433 GB9703433W WO9825886A1 WO 1998025886 A1 WO1998025886 A1 WO 1998025886A1 GB 9703433 W GB9703433 W GB 9703433W WO 9825886 A1 WO9825886 A1 WO 9825886A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound according
thrag
tyrosinase
compound
therapeutically active
Prior art date
Application number
PCT/GB1997/003433
Other languages
French (fr)
Inventor
Patrick Anthony Riley
Andrew Photiou
Tariq Hussain Khan
Helen Mary Isted Osborn
Original Assignee
Patrick Anthony Riley
Andrew Photiou
Tariq Hussain Khan
Helen Mary Isted Osborn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Patrick Anthony Riley, Andrew Photiou, Tariq Hussain Khan, Helen Mary Isted Osborn filed Critical Patrick Anthony Riley
Priority to AT97949046T priority Critical patent/ATE309980T1/en
Priority to DE69734670T priority patent/DE69734670T2/en
Priority to US09/319,866 priority patent/US6573284B1/en
Priority to AU78469/98A priority patent/AU748957B2/en
Priority to EP97949046A priority patent/EP0944583B1/en
Publication of WO1998025886A1 publication Critical patent/WO1998025886A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C07C323/43—Y being a hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C333/00—Derivatives of thiocarbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C333/02—Monothiocarbamic acids; Derivatives thereof
    • C07C333/04—Monothiocarbamic acids; Derivatives thereof having nitrogen atoms of thiocarbamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms

Definitions

  • the present invention relates to novel compounds useful as therapeutic agents and assay reagents. More specifically, the present invention relates to a drug targeting and especially to a novel method of delivery of therapeutically active agents to tumour cells, in particular melanoma cells.
  • Malignant melanoma is an important cancer with a rising incidence worldwide affecting people of all ages, including a relatively young population. Whilst progress is being made in prevention and in early diagnosis, the major problem is the difficulty of treating the disease in its disseminated state. Therapeutic agents with improved effectiveness are urgently required if the number of deaths resulting from malignant melanoma is to be reduced. Melanoma has the potential of rapid metastasis and remains a difficult neoplasm to treat. Conventional antineoplastic agents continue to be of value in the management of this malignancy but improved clinical results can be achieved if established or newly discovered agents are modified to allow them to act more selectively. The delivery of cytotoxic agents to the site of tumour cells is much desired because systemic administration of these agents often results in the killing of normal cells within the body as well as the tumour cells sought to be eliminated.
  • tyrosinase enzyme is differentially associated with certain target cells, especially melanoma cells.
  • tyrosinase (monophenol, 3,4-dihydroxyphenylalanine: oxygen oxidoreductase, EC 1 . 14.1 8. 1 ) is generally exclusive to pigment-producing cells (melanocytes) and is frequently unregulated in melanoma.
  • Use of the catalytic potential of tyrosinase to generate a highly toxic compound from a non-toxic substrate or "prodrug" has been suggested [see Riley PA ( 1 991 ) Eur J Cancer, 27: 1 1 72-1 1 77] and so far, a number of potential melanoma prodrugs have been studied, but with limited success.
  • Such agents include analogues of tyrosine which are oxidised by tyrosinase to generate cytotoxic quinones [see e.g. Naish S, Cooksey CJ & Riley PA ( 1 988) Pig. Cell Res., 1 :3 79-381 ; Naish S, Holden JL, Cooksey CJ & Riley PA ( 1 988) Pig. Cell Res, 1 : 3 8 2-3 8 5] which act through mechanisms leading to thiol depletion [see, e.g.
  • a pro-drug which is capable of releasing a therapeutically active agent at a desired location, characterised in that the pro-drug is a substrate for tyrosinase wherein in the presence of tyrosinase, the compound is oxidised to a quinone, which undergoes cyclisation and hydrolysis to release therapeutically active agent.
  • the invention provides a compound, in particular a prodrug, which is capable of releasing a therapeutically active agent or assayable substance (ThrAg) at a desired location, characterised in that the compound is a substrate for the tyrosinase enzyme and has the formula:
  • B represents a linking group or single bond linking TyrX and ThrAg *, ThrAg * represents a residue of a therapeutically active agent ThrAg or a residue of an indicator molecule, and Y represents -0-, -S- or a group
  • a novel feature of the prodrugs provided in accordance with the invention is the mechanism by which the therapeutically active agent or assayable substance ThrAg is released, allowing in the case where the compound of the invention is a prodrug, targeted delivery of therapeutically active agent. This is based on attachment of the selected agent to the nitrogen atom of the structure TyrX-. This nitrogen atom is involved in cyclization following oxidation by the tyrosinase enzyme, resulting in formation of a group that is susceptible to hydrolysis. On tyrosinase-catalysed oxidation of the pro-drug to the quinone, cyclization produces a positively charged species which undergoes hydrolysis releasing the drug .
  • This mechanism is analogous to the initial phase of melanogenesis which involves the tyrosinase-catalysed oxidation of tyrosine whereby tyrosine is oxidised to the corresponding orthoquinone, which is susceptible to nucleophilic attack .
  • a major pathway involves endogenous cyclization by reductive addition to the ring brought about by the presence of the nucleophilic amino function in the side chain to give rise to cyclodopa.
  • ThrAg may be linked to the optionally substituted tyrosine residue TyrX- by formation of an urethane linkage, TyrX-NH.CO.O-ThrAg * .
  • therapeutically active agents which contain hydroxy groups include oxaliplatin derivatives, vinca alkaloid S1 2363, quercitin, genistein, calcipotriol and 4-hydroxy anisole.
  • therapeutically active agents which contain primary or secondary amino groups include dacarbazine, nifedipine, staurosporin and N- methylarginine.
  • ThrAg can refer to any therapeutically active agent (e.g. a cytotoxic agent), or assayable substance (e.g. an indicator molecule for use in an assay) that can be chemically modified into the pro-drug TyrX-B-ThrAg * .
  • therapeutically active agents and assayable substances ThrAg include:- chemosensitising agents, i.e. chemicals that can make tumour cells sensitive to cytotoxic agents:
  • resistance or multidrug resistance(MDR) modifiers i.e. chemicals that can reverse the effect of multidrug resistance expression in refractory tumour cell lines, leading to a re-sensitisation of the tumour cells to MDR drugs: immunostimulating agents, i.e. chemicals that can prime the immune system, thus triggering an immune system against the tumour, either directly or indirectly incorporation of cytokines into a prodrug structure which can have immunomodulatory activity or other direct/indirect inhibitory actions on cancer cells
  • signal transduction Inhibitors i.e. chemicals that can selectively inhibit vital step/s in signalling pathways, in the normal function of the cancer cell, leading to apoptosis
  • differentiating agents which can include the active metabolite of Vitamin D 3 and novel analogues, retinoic acid and analogues.
  • repair inhibiting drugs which can inhibit the repair of damage induced by chemotherapeutic drugs or radiation
  • prodrugs which when activated lead to a reduction in cellular thiol/sulphhydryl levels
  • prodrugs which when activated will act directly or indirectly on oncogene or tumour suppressor gene or their gene products to influence tumour growth
  • assayable substances or indicator molecules including coloured or fluorescent substances such as fluorescein, raodiolabelled agents, substances which exist in differently coloured forms when free or chemically combined (e.g. dyes in colored and leuko- form), antigenic markers etc.
  • Prodrugs according to the invention mayl be employed either alone or in different combinations and sequences to identify the most effective drug regime.
  • the invention allows the selective delivery of the therapeutically active agent preferentially to those cells containing tyrosinase.
  • the invention has the advantage of not relying on antibodies to target an enzyme to the tumour site, as used in the targeting strategy referred to as ADEPT (Antibody directed enzyme prodrug therapy) .
  • the invention can be applied for therapy to systems where selective expression of tyrosinase can successfully be induced.
  • tyrosinase enzyme inhibitors as small molecules or on polymer supports, can be used in conjunction with the delivery system of the invention to inactivate circulating tyrosinase, as found in melanoma patients, prior to prodrug administration. Such measures will be made to increase the degree of selectivity for melanoma cells in solid tumours.
  • the prodrugs provided according to the invention essentially consist of chemically modified drugs wherein the biological activity of the drug has been substantially eliminated.
  • the unmodified drug is released after the action of the enzyme tyrosinase.
  • the release mechanism of the drug is dependant on the action of the enzyme tyrosinase, and generally occurs by a post enzyme oxidation, cyclization and hydrolysis to release the unmodified drug.
  • tumour cells The action on tumour cells depends on the fact that certain cancer cells contain the enzyme tyrosinase, either naturally as in malignant melanoma or resulting from a spontaneous gene mutation as is reported during dedifferentiation of cancer cells or by transfection of cancer cells as in the use of retrovirus to express tyrosinase in non-pigment producing cancer cells.
  • tyrosinase either naturally as in malignant melanoma or resulting from a spontaneous gene mutation as is reported during dedifferentiation of cancer cells or by transfection of cancer cells as in the use of retrovirus to express tyrosinase in non-pigment producing cancer cells.
  • novel approach to cancer therapy according to the invention is thus based on a tyrosinase-activated drug delivery mechanism which relies on the spontaneous reductive cyclization of dopaquinone (and analogues) to render labile a potentially hydrolysable link between a nitrogen-containing group in the prodrug of formula TyrX-B-ThrAg * .
  • This enables the specific release of the drug in melanogenic cells, as evidenced by data presented herein.
  • prodrugs in accordance with the invention.
  • these include antineoplastic agents which are already in use in the treatment of melanoma. "Combination chemotherapy for disseminated malignant melanoma” . KL Abbott & GS Harman. Anti-cancer drugs 6:489-497) .
  • synthesis of novel prodrugs may lead to the utilization of available antineoplastic agents which are regarded as having no activity against this disease.
  • Vinca alkaloid S 12363.
  • a chemosensitising agent a chemical that can make tumour cells sensitive to cytotoxic agents, such as a resistance or multidrug resistance (MDR) modifier for example Nifedipine and S9788-2.
  • MDR multidrug resistance
  • Nifedipine and S9788-2 a resistance or multidrug resistance modifier
  • Nifedipine and S9788-2 a triazine derivative which contains chemical features known to be important for MDR reversing activity, planar aromatic domain and two amino groups, one having cationic charge at physiological pH.
  • an apoptosis inducing agent such as Staurosporin which inhibits calcium dependant phosphorylation leading to apoptosis of most types of cells.
  • Staurosporin an apoptosis-inducing agent
  • Prodrug site a signal transduction inhibitor, such as Quercetin or Genistein, a chemical that can inhibit the signalling pathway, such as phosphorylation of tyrosine and threonine which is essential for normal cell function.
  • a signal transduction inhibitor such as Quercetin or Genistein
  • an immunostimulating agent a chemical that can prime the immune system, thus triggering the immune system against the tumour, either directly or indirectly.
  • An example of this can be by reducing the levels of Nitric oxide, by inhibiting the enzyme Nitric oxide synthetase with N-methylarginine thus removing the immunosuppressive effect of high levels of Nitric oxide.
  • cytokines TNF- ⁇ , IFN- ⁇ , IFN- or fragments of immunogenic chemicals
  • a differentiating agent which can include the active metabolite of Vitamin D 3 and novel analogues such as Caicipotriol, retinoic ' acid and its analogues.
  • a DNA repair enzyme inhibiting drug such as O6-benzyl-guanine, which can inhibit the enzyme responsible for repairing nuclear DNA damage induced by chemotherapeutic drugs or radiation.
  • BSO Buthionine sulfoximine
  • 4-HYDROXY ANISOLE an antisense molecule, which when activated will act directly or indirectly on oncogene or tumour suppressor gene or their gene products to influence tumour growth.
  • the prodrugs of the invention which can be synthesized by the initial formation of the activated mixed anhydrides of the selected agents which are then converted to the potential prodrug by nucleophilic attack by tyrosine.
  • the general systemic cytotoxicity of the prodrugs will be diminished by incorporation of the reactive functional groups in the covalent bond to the tyrosine.
  • the invention further provides the use of the compounds of the invention in which are capable of conversion to an assayable substance in diagnostic and assay procedures. These include assay procedures for detecting the presence of tyrosinase enzyme in tissue samples and body fluids. In such assays, the sample to be assayed may be contacted with the compound of the invention and following an appropriate incubation period, the release of assayable substance detected. Such procedures are of particular use in the diagnosis of disease states where levels of tyrosinase enzyme are altered, as in melanomas associated with elevated tyurosinase levels.
  • Figure 1 illustrates a reaction scheme (Scheme 1 ) for producing Prodrug A
  • Figure 2 illustrates a reaction scheme (Scheme 2) for producing Prodrug A
  • Figure 3 illustrates a reaction scheme for producing Prodrug B
  • Figure 4 illustrates a reaction scheme for producing Prodrug C

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Novel pro-drugs and assay reagents are provided which are useful as therapeutic agents especially for delivery and targetting therapeutically active agents to melanoma cells. The pro-drugs and assay reagents are substrates for tyrosinase and may be represented by the formula TyrX-B-ThrAg*. The compounds of formula TyrX-B-ThrAg* are capable of releasing a therapeutically active agent or assayable substance (ThrAg) at a desired location, TyrX- being a residue of an optionally substituted tyrosine analogue.

Description

NOVEL COMPOUNDS USEFUL AS THERAPEUTIC AGENTS AND ASSAY REAGENTS
The present invention relates to novel compounds useful as therapeutic agents and assay reagents. More specifically, the present invention relates to a drug targeting and especially to a novel method of delivery of therapeutically active agents to tumour cells, in particular melanoma cells.
BACKGROUND TO THE INVENTION
Malignant melanoma is an important cancer with a rising incidence worldwide affecting people of all ages, including a relatively young population. Whilst progress is being made in prevention and in early diagnosis, the major problem is the difficulty of treating the disease in its disseminated state. Therapeutic agents with improved effectiveness are urgently required if the number of deaths resulting from malignant melanoma is to be reduced. Melanoma has the potential of rapid metastasis and remains a difficult neoplasm to treat. Conventional antineoplastic agents continue to be of value in the management of this malignancy but improved clinical results can be achieved if established or newly discovered agents are modified to allow them to act more selectively. The delivery of cytotoxic agents to the site of tumour cells is much desired because systemic administration of these agents often results in the killing of normal cells within the body as well as the tumour cells sought to be eliminated.
Sadly, treatment of disseminated melanoma is currently inadequate, remaining incurable. Targeted chemotherapy seems a feasible approach for this neoplasm because in the adult human melanogenesis is uniquely a property of melanocytes. Previous attempts at utilization of the melanogenic pathway to activate prodrugs have made use of the formation of reactive quinone intermediates which rely on thiol depletion for their toxic effect and initial attempts to treat melanoma in the clinic have been unsuccessful due to unfavourable pharmacokinetics, low potency and systemic toxicity.
In developing the compounds of the invention, reliance was placed on the realisation that the tyrosinase enzyme is differentially associated with certain target cells, especially melanoma cells.
Thus, tyrosinase (monophenol, 3,4-dihydroxyphenylalanine: oxygen oxidoreductase, EC 1 . 14.1 8. 1 ) is generally exclusive to pigment-producing cells (melanocytes) and is frequently unregulated in melanoma. Use of the catalytic potential of tyrosinase to generate a highly toxic compound from a non-toxic substrate or "prodrug" has been suggested [see Riley PA ( 1 991 ) Eur J Cancer, 27: 1 1 72-1 1 77] and so far, a number of potential melanoma prodrugs have been studied, but with limited success. Examples of such agents include analogues of tyrosine which are oxidised by tyrosinase to generate cytotoxic quinones [see e.g. Naish S, Cooksey CJ & Riley PA ( 1 988) Pig. Cell Res., 1 :3 79-381 ; Naish S, Holden JL, Cooksey CJ & Riley PA ( 1 988) Pig. Cell Res, 1 : 3 8 2-3 8 5] which act through mechanisms leading to thiol depletion [see, e.g. Alena F, Iwashina T, Gili A & Jimbow K ( 1 994) Cancer Res., 54(1 0) : 2661 -2666; Alena F, Dixon W, Thomas P & Jimbow K (1 995) J. Invest. Dermatol., 104(5) : 792-797; Riley PA, Cooksey CJ, Johnson CI, Land EJ, Latter AM & Ramsden CA ( 1 996) Eur. J. Cane, (in press)].
Initial studies indicated that compounds such as 4-hydroxyanisole held promise in targeted melanoma chemotherapy [see Morgan BDG, O'Neill T, Dewey DL, Galpine AR & Riley PA ( 1 981 ) Clin. Oncol., 7:227-234], but a number of serious difficulties have been encountered in the clinic, notably the relatively limited cytotoxicity of the resulting cytotoxic quinone, necessitating the use of high serum levels of the prodrug and complications from systemic actions [see Rustin GJ, Stratford MR, Lamont A, Bleehen N, Philip PA, Howells N, Wafta RR & Slack JA ( 1 992) Eur. J. Cane, 28A, 1 362-1 364; Belcher HJ, Nizam M & ONeill TJ ( 1 992) Br. J. Plast. Surg ., 45:208-21 0] due to alternative metabolism, particularly hepatic and renal toxicity [see Schiller CD, Gesher A & Jheeta P (1 991 ) Eur. J. Cane, 27: 1 01 7-1 022; Stolze K & Nohl H ( 1 991 ) Free Rad. Res. Comm., II: 321 -327. Refs. 1 7, 1 8].
Therefore, in order for tyrosinase-dependent activation of cytotoxic pro- drugs is to become an effective and realistic chemotherapeutic targeting strategy for the treatment of melanoma, there has been a need for agents to be developed that produce their action by a mechanism that does not rely for its cytotoxic effect on thiol depletion.
The basis of our new approach to lethal synthesis in melanogenic cells, which to our knowledge has not hitherto been studied, is the utilization of the reductive cyclization process associated with the tyrosinase enzyme to initiate the specific intracellular release of cytotoxic agents. By this approach, we have succeeded in incorporating in a prodrug known cytotoxic compounds whose behaviour on release are well understood and which have been proven as potent inhibitors of tumour growth. The modification of the chemical structure of the active agent by incorporation in the prodrug is designed to moderate its cytotoxicity whilst it is in the form of the prodrug by diminishing its reactivity and by reduction of systemic bioavailability through effects on half-life or altered cellular uptake characteristics. The targetted release mechanism proposed is aimed at selectively liberating the drug from these constraints.
It is one aim of the present invention to produce and screen a novel category of anti-melanoma compounds. A further object is to provide novel compounds useful as assay or diagnostic agents. The approach that we adopted was based on our appreciation that the structural requirements for compounds to act as substrates for tyrosinase could be adapted to the synthesis of prodrugs. SUMMARY OF THE INVENTION
The present invention provides a novel class of compounds which depend upon the action of tyrosinase for their conversion to desired products, including therapeutically active substances and assayable metabolites, e.g . indicator molecules.
Thus according to one aspect of the invention there is provided a pro-drug which is capable of releasing a therapeutically active agent at a desired location, characterised in that the pro-drug is a substrate for tyrosinase wherein in the presence of tyrosinase, the compound is oxidised to a quinone, which undergoes cyclisation and hydrolysis to release therapeutically active agent.
According to a further aspect of the invention there is provided a compound which is capable of conversion to an assayable substance such as an indicator molecule, characterised in that the compound is a substrate for tyrosinase wherein in the presence of tyrosinase, the compound is oxidised to a quinone, which undergoes cyclisation and hydrolysis to release said assayable substance.
More specifically, the invention provides a compound, in particular a prodrug, which is capable of releasing a therapeutically active agent or assayable substance (ThrAg) at a desired location, characterised in that the compound is a substrate for the tyrosinase enzyme and has the formula:
TyrX-B-ThrAg * wherein TyrX- is a residue of an optionally substituted tyrosine analogue of the structure
Figure imgf000006_0001
wherein each of the symbols = Z- is independently selected from = CH-, = C-,
= N-, and -N + = O, B represents a linking group or single bond linking TyrX and ThrAg *, ThrAg * represents a residue of a therapeutically active agent ThrAg or a residue of an indicator molecule, and Y represents -0-, -S- or a group
Figure imgf000007_0001
n is 1 , 2, 3 or 4 (preferably 1 or 2), and either NQ- represents -N- and the dotted line represents a bond linking the nitrogen atom to the indicated ring atom or NQ- represents -NR6- and the dotted line is to be ignored, R1 and R2 independently represent hydrogen, halogen (e.g. F, CI, Br or I) or -OH,
R , R , and R independently represent hydrogen, halogen (e.g. F, CI, Br or I), Cr 4 alkyl, C^ alkeπyl, CF3, NO2, -OH,- COOH, -COOR, or -CH2OH, wherein R represents C,.4 alkyl, and R6 represents hydrogen, halogen (e.g. F, CI, Br or I), C,.4 alkyl, C1 -4 alkenyl, CF3,
NO2, -OH, -COOH, -CH2OH, -COOR, -OR, -SR or -SeR wherein R represents
C,.4 alkyl, and wherein in the presence of tyrosinase, the compound TyrX-B-ThrAg * is oxidised to a quinone, which undergoes cyclization and hydrolysis to release ThrAg.
R1 and R2 are preferebly selected from H and OH. R3 and R4 are preferably selected from H and -CH3# R5 is preferably selected from H or -COOH. R6 is preferably selected from H, CH3 and -OCH3. Most preferably, TyrX is an optionally substituted tyrosine analogue having one of the following structures, wherein = Z-, NY, Q, B, R, , R2, R3, R4, R5, R6 and n are as defined above
Figure imgf000008_0001
Figure imgf000008_0002
Figure imgf000008_0003
Figure imgf000008_0004
Examples of linking groups B include:
O O S 0 S
I I ι | I I I i
C-O- C- C-NH- and C-NH
A novel feature of the prodrugs provided in accordance with the invention is the mechanism by which the therapeutically active agent or assayable substance ThrAg is released, allowing in the case where the compound of the invention is a prodrug, targeted delivery of therapeutically active agent. This is based on attachment of the selected agent to the nitrogen atom of the structure TyrX-. This nitrogen atom is involved in cyclization following oxidation by the tyrosinase enzyme, resulting in formation of a group that is susceptible to hydrolysis. On tyrosinase-catalysed oxidation of the pro-drug to the quinone, cyclization produces a positively charged species which undergoes hydrolysis releasing the drug .
This mechanism is analogous to the initial phase of melanogenesis which involves the tyrosinase-catalysed oxidation of tyrosine whereby tyrosine is oxidised to the corresponding orthoquinone, which is susceptible to nucleophilic attack . A major pathway involves endogenous cyclization by reductive addition to the ring brought about by the presence of the nucleophilic amino function in the side chain to give rise to cyclodopa.
The manner in which the therapeutically active agent or assayable substance ThrAg is chemically linked to the residue of the optionally substituted tyrosine analogueTyrX- will depend upon the structure of ThrAg and in particular on the availability of chemically reactive groups therein.
Thus for example, if the therapeutically active agent or assayable substance ThrAg contains a carboxy group -COOH, ThrAg may be linked to the optionally substituted tyrosine residue TyrX- by formation of an amide linkage, TyrX-NH.CO-ThrAg * . Examples of therapeutically active agents which contain carboxy groups include betulinic acid and retinoic acid.
Alternatively, if the therapeutically active agent or assayable substance ThrAg contains a hydroxy group -OH, ThrAg may be linked to the optionally substituted tyrosine residue TyrX- by formation of an urethane linkage, TyrX-NH.CO.O-ThrAg * .
Examples of therapeutically active agents which contain hydroxy groups include oxaliplatin derivatives, vinca alkaloid S1 2363, quercitin, genistein, calcipotriol and 4-hydroxy anisole.
By way of further example, if the therapeutically active agent or assayable substance ThrAg contains a primary or secondary amino group -NH2 or -NH-, ThrAg may be linked to the optionally substituted tyrosine residue TyrX- by formation of secondary or tertiary amino linkages TyrX-NH-ThrAg * or TyrX-N = ThrAg * . Examples of therapeutically active agents which contain primary or secondary amino groups include dacarbazine, nifedipine, staurosporin and N- methylarginine.
More generally, the abbreviation "ThrAg" can refer to any therapeutically active agent (e.g. a cytotoxic agent), or assayable substance (e.g. an indicator molecule for use in an assay) that can be chemically modified into the pro-drug TyrX-B-ThrAg * . Further classes of therapeutically active agents and assayable substances ThrAg include:- chemosensitising agents, i.e. chemicals that can make tumour cells sensitive to cytotoxic agents:
resistance or multidrug resistance(MDR) modifiers, i.e. chemicals that can reverse the effect of multidrug resistance expression in refractory tumour cell lines, leading to a re-sensitisation of the tumour cells to MDR drugs: immunostimulating agents, i.e. chemicals that can prime the immune system, thus triggering an immune system against the tumour, either directly or indirectly incorporation of cytokines into a prodrug structure which can have immunomodulatory activity or other direct/indirect inhibitory actions on cancer cells
signal transduction Inhibitors, i.e. chemicals that can selectively inhibit vital step/s in signalling pathways, in the normal function of the cancer cell, leading to apoptosis
differentiating agents, which can include the active metabolite of Vitamin D3 and novel analogues, retinoic acid and analogues.
repair inhibiting drugs, which can inhibit the repair of damage induced by chemotherapeutic drugs or radiation
prodrugs which when activated lead to a reduction in cellular thiol/sulphhydryl levels
prodrugs which when activated will act directly or indirectly on oncogene or tumour suppressor gene or their gene products to influence tumour growth
assayable substances or indicator molecules, including coloured or fluorescent substances such as fluorescein, raodiolabelled agents, substances which exist in differently coloured forms when free or chemically combined (e.g. dyes in colored and leuko- form), antigenic markers etc.
Prodrugs according to the invention mayl be employed either alone or in different combinations and sequences to identify the most effective drug regime. The invention allows the selective delivery of the therapeutically active agent preferentially to those cells containing tyrosinase. The invention has the advantage of not relying on antibodies to target an enzyme to the tumour site, as used in the targeting strategy referred to as ADEPT (Antibody directed enzyme prodrug therapy) .
The invention in a preferred embodiment provides a selective method for the treatment of malignant melanoma, an aggressive tumour which contains the enzyme tyrosinase. The invention may also be applicable for the treatment of other malignancies where tyrosinase is present in tumour cells, in particular breast carcinoma. The rapid expansion of the area of molecular biology and more specifically the use of retroviruses to transform cells into tyrosinase producing type, would allow a wide variety of future applications for our novel drug delivery system.
The invention can be applied for therapy to systems where selective expression of tyrosinase can successfully be induced. Furthermore, the use of tyrosinase enzyme inhibitors, as small molecules or on polymer supports, can be used in conjunction with the delivery system of the invention to inactivate circulating tyrosinase, as found in melanoma patients, prior to prodrug administration. Such measures will be made to increase the degree of selectivity for melanoma cells in solid tumours.
It will be appreciated that the prodrugs provided according to the invention essentially consist of chemically modified drugs wherein the biological activity of the drug has been substantially eliminated. After administration the unmodified drug is released after the action of the enzyme tyrosinase. The release mechanism of the drug is dependant on the action of the enzyme tyrosinase, and generally occurs by a post enzyme oxidation, cyclization and hydrolysis to release the unmodified drug. The action on tumour cells depends on the fact that certain cancer cells contain the enzyme tyrosinase, either naturally as in malignant melanoma or resulting from a spontaneous gene mutation as is reported during dedifferentiation of cancer cells or by transfection of cancer cells as in the use of retrovirus to express tyrosinase in non-pigment producing cancer cells.
The novel approach to cancer therapy according to the invention is thus based on a tyrosinase-activated drug delivery mechanism which relies on the spontaneous reductive cyclization of dopaquinone (and analogues) to render labile a potentially hydrolysable link between a nitrogen-containing group in the prodrug of formula TyrX-B-ThrAg * . This enables the specific release of the drug in melanogenic cells, as evidenced by data presented herein.
As indicated previously a wide range of therapeutically active substances can be chemically modified to form prodrugs in accordance with the invention. Preferably, these include antineoplastic agents which are already in use in the treatment of melanoma. "Combination chemotherapy for disseminated malignant melanoma" . KL Abbott & GS Harman. Anti-cancer drugs 6:489-497) . However synthesis of novel prodrugs may lead to the utilization of available antineoplastic agents which are regarded as having no activity against this disease.
Figure imgf000013_0001
site NOVEL TETRAPLATIN
Prodrug NOVEL OXALIPLATIN
Figure imgf000014_0001
Vinca alkaloid, S 12363. An example of an agent which is too active for clinic use. Modification/incorporation of this type of molecule may provide a potent active agent being released at the tumour site.
Figure imgf000014_0002
analoques of Dacarbazine 5-(3,3- Dimethyl- 1 -triazenyl)- 1 -H-imidazole -4-carboxamide (DTIC) Furthermore, the therapeutically active agent can-also refer to:
a chemosensitising agent, a chemical that can make tumour cells sensitive to cytotoxic agents, such as a resistance or multidrug resistance (MDR) modifier for example Nifedipine and S9788-2. the latter being a triazine derivative which contains chemical features known to be important for MDR reversing activity, planar aromatic domain and two amino groups, one having cationic charge at physiological pH. These agents can reverse the effect of multidrug resistance expression in refractory tumour cell lines, leading to a re-sensitisation of the tumour cells to MDR drugs:
Figure imgf000015_0001
N ifed ipine
S9788-2
an apoptosis inducing agent, such as Staurosporin which inhibits calcium dependant phosphorylation leading to apoptosis of most types of cells.
Prodrug site __
Staurosporin an apoptosis-inducing agent
Figure imgf000015_0002
Prodrug site a signal transduction inhibitor, such as Quercetin or Genistein, a chemical that can inhibit the signalling pathway, such as phosphorylation of tyrosine and threonine which is essential for normal cell function.
TYROSINE KINASF. INHIBITORS
Figure imgf000016_0001
GENISTEIN
Figure imgf000016_0002
an immunostimulating agent, a chemical that can prime the immune system, thus triggering the immune system against the tumour, either directly or indirectly. An example of this can be by reducing the levels of Nitric oxide, by inhibiting the enzyme Nitric oxide synthetase with N-methylarginine thus removing the immunosuppressive effect of high levels of Nitric oxide.
Figure imgf000016_0003
Prodrug site
NG-monomethyl-L-arginine
incorporation of cytokines (TNF-σ, IFN-σ, IFN- or fragments of immunogenic chemicals) into a prodrug structure which can have immunomodulatory activity or other direct/indirect inhibitory actions on cancer cells.
a differentiating agent, which can include the active metabolite of Vitamin D3 and novel analogues such as Caicipotriol, retinoic' acid and its analogues.
TE
Figure imgf000017_0001
a DNA repair enzyme inhibiting drug, such as O6-benzyl-guanine, which can inhibit the enzyme responsible for repairing nuclear DNA damage induced by chemotherapeutic drugs or radiation.
a chemical, such as p-hydroxy anisole which when activated to the quinone leads to a reduction in cellular thiol/sulphhydryl levels rendering cells more susceptible to damage by chemical agents. Use of analogues of Buthionine sulfoximine (BSO) a glutamyl cysteine synthetase to reduce the level of cellular glutathinone synthesis (Kable et al [1 989] Cancer Res, 49: 2327-2331 )
Prodrug site *■
Figure imgf000017_0002
4-HYDROXY ANISOLE an antisense molecule, which when activated will act directly or indirectly on oncogene or tumour suppressor gene or their gene products to influence tumour growth.
The prodrugs of the invention which can be synthesized by the initial formation of the activated mixed anhydrides of the selected agents which are then converted to the potential prodrug by nucleophilic attack by tyrosine. The general systemic cytotoxicity of the prodrugs will be diminished by incorporation of the reactive functional groups in the covalent bond to the tyrosine. The invention further provides the use of the compounds of the invention in which are capable of conversion to an assayable substance in diagnostic and assay procedures. These include assay procedures for detecting the presence of tyrosinase enzyme in tissue samples and body fluids. In such assays, the sample to be assayed may be contacted with the compound of the invention and following an appropriate incubation period, the release of assayable substance detected. Such procedures are of particular use in the diagnosis of disease states where levels of tyrosinase enzyme are altered, as in melanomas associated with elevated tyurosinase levels.
DESCRIPTION OF FIGURES
The invention will now be described in more detail by reference to the appended Figures as well as in the following examples and descriptions of pilot studies, and chemical and biological tests. The Synthesis Examples illustrate the preparation of prodrugs in accordance with the invention.
In the Figures,
Figure 1 illustrates a reaction scheme (Scheme 1 ) for producing Prodrug A
Figure 2 illustrates a reaction scheme (Scheme 2) for producing Prodrug A
Figure 3 illustrates a reaction scheme for producing Prodrug B
Figure 4 illustrates a reaction scheme for producing Prodrug C
Figure 5 illustrates the rsults of oximetry measurements on representative compounds Figure 6 illustrates the results of MTBH assays on five cell lines Figure 7 illustrates the results of cytotoxicity tests
Figures 8 & 9 illustrates the results of experiments demonstrating the release of drug from prodrug EXAMPLES
A. Pilot Study
To test the feasibility of the tyrosinase-activated drug-release mechanism, a prodrug analogue was synthesized by covalent addition of 4-nitrophenyl isothiocyanate and dopamine. This yellow prodrug analogue was tested to establish whether, on oxidation and cyclization according to our proposed mechanism, it would yield the orange hydrolysis product 4-nitroaniline.
The prodrug analogue was stable in solution at pH 6.5 for up to 1 2 hours, but on addition of tyrosinase, an orange product was formed. Extraction with ethyl acetate isolated a compound different from the prodrug with strong absorption at 365nm and properties consistent with 4-nitroaniline.
B. Synthesis Examples
1 . Synthesis of N-(N-bis-chlorethyl-4-amino-phenyloxycarbonyl)-3- hydroxy-tyramine (Prodrug A - Scheme 1 )
Figure imgf000019_0001
1 .Og, 5.27mmol of 3-hydroxytyramine hydrochloride was mixed with 20ml of dry dichloromethane. To the stirred suspension 1 ml of triethylamine was added, followed by 1 ml of pyridine. The suspension was stirred for 5 min and then mixed with 2.32g , 5.27mmol of N-bis-chloroethyl-aminophenyloxy- p-nitro- phenyloxycarobonate. The suspension was stirred for 4 days at room temperature. The deep yellow solution was concentrated in vacuo. The residue was dissolved in ethyl acetate and washed with 0.1 M hydrochloric acid, 0.5 M sodium hydrogencarbonate solution, and distilled water. The organic fraction was dried over sodium sulphate, filtered and concentrated in vacua. The residue was chromatographed on silica gel using gradient elution with ethylacetate and ethanol, resulting in 490mg of a yellow solid. Rf = 0.7( 1 : 1 Ethylacetate: Ethanol), Mpt = 80°C (dec), 1 HNMR (D6 DMSO) :-
Modified synthesis of p-IM,l\l-Bis-chloroethyl-amino-phenoxy-carbonyl-p- nitrophenoxide (Prodrug A - Scheme 2)
To a refluxing solution of p-nitrophenol chloroformate (4g, .002mol) in benzene (50ml) , a solution of N, N-bis-chloroethyl-aminophenoxide triethylammonium salt (5.4g, 0.02mol) in benzene (60ml) was added dropwise over 1 5 min. The reaction mixture was refluxed under an inert atmosphere for 2 hs. The cooled reaction mixture was concentrated in-vacuo and chromatographed on silica using dichloromethane. The product was isolated from the early fractions ( 1 - 6) and then solidified with hexane. The required product was crystallised from benzene/hexane to result in a total of 7g p-N,N-bis-chloroethyl-aminophenoxy- carbonyl-p-nitrophenoxide (80% yield , Rf = 0.63 (CH2CI2) .
C. Silver Oxide Oxidation
Since the initial experiment provided evidence of the postulated reaction mechanism a prodrug containing an alkylating agent was synthesized (Compound A above) . Chemical investigations showed that after silver oxide oxidation two compounds are liberated at pH 6.0 one polar with characteristics of the indole produced during the cyclization and hydrolysis reaction and one less polar with an Rf on thin layer chromatography similar to the mustard drug (Compound C) .
Figure imgf000020_0001
compound C D. BIOLOGICAL METHODS
1 . Oximetry
To test the selectivity of the tyrosinase-activated delivery system, the ability of mushroom tyrosinase to catalyse the oxidation of various substrates was further examined by oximetry. The substrates tested were tyrosine (the normal enzyme substrate), Compound A, 4-hydroxyanisole and N-acetyl tyrosine.
The method of oximetry used has been described previously (Naish-Byfield & Riley 1 992, Biochem J.288:763-67; Naish-Byfield et al 1 994, Biochem J. 304: 1 55-1 62) . Mushroom tyrosinase was obtained from Sigma, UK. Specific activity of the enzyme was 2200 units/mg of protein. The standard reaction mixture was made up of 2ml of 1 00//M of substrates (200nmol/reaction) and 1 65 units of tyrosinase/ml added in volume of 200 I. The reaction was performed in an oxygen- electrode chamber at room temperature. The utilization of oxygen with respect to time was monitored using a standard oxygen probe.
The results showed that Compound A is oxidised by tyrosinase, although the rate of the reaction was lower than for the normal substrate. 4-Hydroxyanisole and N-acetyl tyrosine were also oxidised, but at a lower rate than tyrosine.
2. Tyrosinase activity of test cell lines
The tyrosinase activity of five cell lines was measured when in logarithmic phase of growth. The tyrosinase activity was measured using the MBTH assay which has been described previously (Pifferi & Baldassari 1 973, 52:325-335) . Briefly tyrosinase activity is estimated by using Besthorn's hydrazone which indicates the generation of quinone formation. The comparative tyrosinase activity of the five cell lines, as estimated by the MBTH assay is shown in Fig 6 It can be seen that the three melanoma cell lines, C32, G361 and StMH 1 a exhibited a high level of tyrosinase activity. The cell line Caki-1 (a renal cell carcinoma line) showed a small, but nonetheless measurable level of tyrosinase activity. The CHO cell line showed no detectable tyrosinase activity.
3. Measurement of growth inhibition (cytotoxicity)
The activities of the prodrug A, Compound B and the reference drug C, were compared for their ability to produce growth inhibition of human melanoma (C32, G361 and STMI 1 la) and nonmelanoma derived cell lines (Caki-2 and CHO) in vitro.
Figure imgf000022_0001
Growth inhibition was measured using the Sulpforhodamine B (SRB) assay as previously described (Skehan et al 1 990; J.Natl Cancer Inst 82: 1 107-1 1 1 2; Houghton et al 1 994; Pianta Medica. 60: 430-433) . Cell lines C32 and Caki-2 were obtained from the ETCC (PHLS, Porton Down, UK) . StM 1 1 1 a was kindly received from Dr. Zouboulis, Dept of Dermatology, Free University of Berlin, Germany. CHO cells were obtained from Dr. Smith, Richard Dimbleby Dept of Cancer Research, St Thomas Hospital, London. Cells were maintained in RPMI- 1 640 containing 1 0% heat-inactivated FCS, 2mM L-glutamine, 50 lU/ml penicillin, 50 μg/ml streptomycin and 2.5 μg/ml amphotericin B, (Hycione, UK) . Cultures were incubated at 37°C in 5 % CO2 in a humidified atmosphere. The SRB assay estimates cell number indirectly by measuring total basic amino acids. Certain criteria were satisfied before using this technique. Firstly, it was established that optical density was directly proportional to cell number up to the density reached by the end of the assay. Secondly, an optimal starting density was found which allowed cells to remain in log-phase throughout the treatment and post-treatment period. Cultures were exposed to the test substances for 1 hr, a day after being plated. Assays were terminated 6 days after treatment, a period equivalent to 4-5 doubling times .
The activity of test substances A, B & C were compared by determination of the IC50 value (concentration necessary to inhibit 50% of growth) .
The relative toxicity of compounds A, B and C in each cell line (expressed as the inverse of the IC50 determined by the sulphorhodamine assay after four hours exposure to the agents) is illustrated by the bar chart in Fig 7. The data show that Compound B is essentially non-toxic compared to the reference Compound C, which exhibits an IC50 between 1 -2 /M in all cell lines.
By contrast Compound A (a prodrug according to the invention) is relatively non-toxic in non-melanogenic cells, but exhibits increasing toxicity with tyrosinase activity in the melanoma cell lines.
These data are entirely consistent with the postulated mechanism of the prodrugs of the invention and the cytotoxicity results are encouraging in demonstrating selective toxicity towards melanogenic cells.
E. RELEASE OF DRUG FROM PRODRUG (1 ) UPON TREATMENT WITH TYROSINASE
Figure imgf000024_0001
RMM = 233, 235 (Two isotopes of Cl)
Prodrug (1) (2 mg,' 5.,l x 10"6 mol) was dissolved in DMSO (0.2 cm3) and treated with a suspension of tyrosinase (2 mg, from Sigma) in phosphate buffer (0.2 cm3, pH 7.2, from Aldrich). The resulting suspension was stirred at 25 °C for 1 hour. The reaction mixture was then analysed by thin layer chromatography, which demonstrated that a component of identical Rf to the authentic mustard drug had been produced during this process. The solution was further analysed by GCMS (Fisons GC 8000 and Trio 1000 Mass Spectrometer using El conditions) using an initial oven temperature of 150 °C for 5 minutes. The temperature was then raised from 150 °C to 250 °C over 5 minutes, and then maintained at 250 "C. Under these conditions, both the authentic mustard~drug and the drug which was released during the enzyme treated prodrug experiment had a retention time of 10.2 minutes. Furthermore, the mass spectra obtained from both the authentic and released mustard drug were identical and showed the expected isotope pattern for chlorine containing compounds, m / z (El) 235 (M+), 233 (M+), 186 (M-CH C1), 184 (M-CH2C1), 148 (M-CH2-2C1) and 120.
F. SUMMARY
By way of summary, preliminary findings from the pilot study supports the feasibility of the novel drug delivery mechanism of the invention and these preliminary results were confirmed by the biological test procedures described herein.
It is envisaged that a range of agents with different modes of action can be incorporated in targeted prodrugs based on this release mechanism of the invention, including established cytotoxic agents with antimelanoma action such as mustards, nitrosoureas, vinca alkaloids and taxanes, novel plant products (betulinic acid which has some selectivity towards melanoma) as well as agents that modify the behaviour or sensitivity of tumour cells [see. e.g. Abbott KL & Harman GS ( 1 995) Anti-Cancer Drugs, 6: 489-497] . These can include P1 70- multidrug resistance modifiers, inhibitors of DNA repair and modifiers of intracellular glutathione levels. We have found that melanoma can be sensitized to MDR-drugs in the absence of any staining for the MDR phenotype which is not normally detected by immunohistochemistry and western blotting. Our initial studies have concentrated on agents with known modes of action and relatively simple structures such as mustards and nitrosoureas which should present few synthetic obstacles. Those of skill in the art will readily be able to devise analogous synthetic schemes.

Claims

1 . A pro-drug which is capable of releasing a therapeutically active agent at a desired location, characterised in that the pro-drug is a substrate for tyrosinase wherein in the presence of tyrosinase, the prodrug is oxidised to a quinone, which undergoes cyclisation and hydrolysis to release therapeutically active agent.
2. A compound which is capable of conversion to an assayable substance such as an indicator molecule, characterised in that the compound is a substrate for tyrosinase wherein in the presence of tyrosinase, the compound is oxidised to a quinone, which undergoes cyclisation and hydrolysis to release said assayable substance.
3. A compound which is capable of releasing a therapeutically active agent or assayable substance (ThrAg) at a desired location, characterised in that the compound is a substrate for the tyrosinase enzyme and has the formula:
TyrX-B-ThrAg * wherein TyrX- is a residue of an optionally substituted tyrosine analogue of the structure
Figure imgf000026_0001
wherein each of the symbols = Z- is independently selected from = CH-, = C-, = N-, and -N + = O, B represents a linking group or single bond linking TyrX and ThrAg *, ThrAg * represents a residue of a therapeutically active agent ThrAg or a residue of an indicator molecule, and Y represents -O-, -S- or a group
Figure imgf000027_0001
n is 1 , 2, 3 or 4 (preferably 1 or 2), and either NQ- represents -N- and the dotted line represents a bond linking the nitrogen atom to the indicated ring atom or NQ- represents -NR6- and the dotted line is to be ignored, R1 and R2 independently represent hydrogen, halogen (e.g. F, Cl, Br or I) or -OH, R3, R4, and R5 independently represent hydrogen, halogen (e.g. F, Cl, Br or I), C1 -4 alkyl, C^ alkenyl, CF3, NO2, -OH,- COOH, -COOR, or -CH2OH, wherein R represents C^ alkyl, and R6 represents hydrogen, halogen (e.g. F, Cl, Br or I), C1 -4 alkyl, C.,.4 alkenyl, CF3,
NO2, -OH, -COOH, -CH2OH, -COOR, -OR, -SR or -SeR wherein R represents
C,.4 alkyl, and wherein in the presence of tyrosinase, the compound TyrX-B-ThrAg * is oxidised to a quinone, which undergoes cyclization and hydrolysis to release ThrAg.
4. A compound according to Claim 3 wherein B represents
O O s O S c- C-O- c- C-NH- or C-NH
5. A compound according to Claim 3 having the formula
Figure imgf000028_0001
wherein = Z-, NQ, R R2, R3, R4 and n are as defined in Claim 3.
A compound according to Claim 3 having the formula
Figure imgf000028_0002
wherein = Z-, NQ, Rv R2, R3, R4 and n are as defined in Claim 3.
A compound according to Claim 3 having the formula
Figure imgf000028_0003
wherein = Z-, R, and R2 are as defined in Claim 3.
8. A compound according to any of Claims 3 to 7 wherein R, and R2 are selected from H and OH.
9. A compound according to to any of Claims 3 to 8 wherein R3 and R4 are selected from H and CH3.
10. A compound according to any of Claims 3 to 9 wherein R R2 , R3 , R4, R5 and R6 are hydrogen.
1 1 . A compound according to any preceding claim wherein n is 1 .
1 2. A compound according to any preceding claim wherein B represents a single bond.
1 3. A compound according to any of Claims 3 to 1 2 wherein the therapeutically active agent has the formula NH2-ThrAg * .
1 4. A compound according to any of Claim 3 to 1 2 wherein B represents - NH-CO-.
1 5. A compound according to any of Claims 3 to 1 2 wherein the therapeutically active agent has the formula HO-ThrAg * .
1 6. A compound according to any preceding claim having one of the following formulae:
Figure imgf000029_0001
Figure imgf000030_0001
Figure imgf000030_0002
17. A compound according to Claim 3 having one of the following formulae
Figure imgf000030_0003
1 8. A compound according to any of claims 1 to 1 3 wherein THrAg is a cytotoxic drug.
1 9. A compound according to any of Claims 3 to 1 8 which is a prodrug.
20. The use of a pro-drug as claimed in Claim 1 or Claim 1 9 in the manufacture of a pharmaceutical composition for treating melanoma.
21 . The use of a compound according to any of Claims 2 to 1 6 in an assay procedure for detecting the presence of tyrosinase enzyme in tissue samples and body fluids.
PCT/GB1997/003433 1996-12-13 1997-12-12 Novel compounds useful as therapeutic agents and assay reagents WO1998025886A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AT97949046T ATE309980T1 (en) 1996-12-13 1997-12-12 PREPARATIONS FOR USE AS THERAPEUTIC AND DETECTION AGENTS
DE69734670T DE69734670T2 (en) 1996-12-13 1997-12-12 PREPARATIONS FOR USE AS THERAPEUTIC AND REFERENCES
US09/319,866 US6573284B1 (en) 1996-12-13 1997-12-12 Method of treating melanoma
AU78469/98A AU748957B2 (en) 1996-12-13 1997-12-12 Novel compounds useful as therapeutic agents and assay reagents
EP97949046A EP0944583B1 (en) 1996-12-13 1997-12-12 Novel compounds useful as therapeutic agents and assay reagents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9625895.9 1996-12-13
GBGB9625895.9A GB9625895D0 (en) 1996-12-13 1996-12-13 Novel compound useful as therapeutic agents and assay reagents

Publications (1)

Publication Number Publication Date
WO1998025886A1 true WO1998025886A1 (en) 1998-06-18

Family

ID=10804381

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1997/003433 WO1998025886A1 (en) 1996-12-13 1997-12-12 Novel compounds useful as therapeutic agents and assay reagents

Country Status (7)

Country Link
US (1) US6573284B1 (en)
EP (1) EP0944583B1 (en)
AT (1) ATE309980T1 (en)
AU (1) AU748957B2 (en)
DE (1) DE69734670T2 (en)
GB (1) GB9625895D0 (en)
WO (1) WO1998025886A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002008174A1 (en) * 2000-07-26 2002-01-31 Patrick Anthony Riley Phenylethylamine derivatives and their use in the treatment of melanoma

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040014652A1 (en) * 2000-06-01 2004-01-22 Andre Trouet Tumor activated prodrug compounds and methods of making and using the same
JP3950046B2 (en) * 2000-09-21 2007-07-25 ファイザー・プロダクツ・インク Resorcinol derivative
KR101064901B1 (en) * 2003-03-20 2011-09-16 나노캐리어 가부시키가이샤 Micellar Preparation Containing Sparingly Water-soluble Anticancer Agent And Novel Block Copolymer
MXPA06008293A (en) 2004-01-22 2007-06-11 Univ Miami Topical co-enzyme q10 formulations and methods of use.
PL1792927T3 (en) 2004-09-22 2013-09-30 Nippon Kayaku Kk Novel block copolymer, micelle preparation, and anticancer agent containing the same as active ingredient
CA2652656A1 (en) * 2006-05-18 2007-11-29 Nippon Kayaku Kabushiki Kaisha High-molecular weight conjugate of podophyllotoxins
CA2664852A1 (en) * 2006-10-03 2008-04-10 Nippon Kayaku Kabushiki Kaisha High-molecular weight conjugate of resorcinol derivatives
BRPI0809164B8 (en) 2007-03-22 2023-02-28 Berg Llc COMPOSITION FOR TOPICAL ADMINISTRATION AND PHARMACEUTICAL COMPOSITION COMPRISING SAID COMPOSITION
USRE46190E1 (en) 2007-09-28 2016-11-01 Nippon Kayaku Kabushiki Kaisha High-molecular weight conjugate of steroids
US8920788B2 (en) * 2008-03-18 2014-12-30 Nippon Kayaku Kabushiki Kaisha High-molecular weight conjugate of physiologically active substances
JP6058263B2 (en) 2008-04-11 2017-01-11 バーグ リミテッド ライアビリティ カンパニー Methods and uses for inducing apoptosis in cancer cells
EP2284209B1 (en) * 2008-05-08 2016-08-31 Nippon Kayaku Kabushiki Kaisha Polymer conjugate of folic acid or folic acid derivative
AU2010247750B2 (en) 2009-05-11 2016-09-22 Berg Llc Methods for treatment of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
EP2431403B1 (en) 2009-05-15 2016-09-28 Nipponkayaku Kabushikikaisha Polymer conjugate of bioactive substance having hydroxy group
EA032941B1 (en) * 2010-03-12 2019-08-30 БЕРГ ЭлЭлСи INTRAVENOUS FORMULATIONS OF COENZYME Q10 (CoQ10) AND USE THEREOF
CN103221054A (en) 2010-11-17 2013-07-24 日本化药株式会社 Novel polymer derivative of cytidine metabolism antagonist
AU2012240222B2 (en) 2011-04-04 2017-04-27 Berg Llc Methods of treating central nervous system tumors
PE20140628A1 (en) 2011-06-17 2014-05-30 Berg Llc INHALABLE PHARMACEUTICAL COMPOSITIONS
BR112014005452B1 (en) 2011-09-11 2021-03-16 Nippon Kayaku Kabushiki Kaisha block copolymer production method
SG10201903112WA (en) 2013-04-08 2019-05-30 Berg Llc Treatment of cancer using coenzyme q10 combination therapies
CN105705162A (en) 2013-09-04 2016-06-22 博格有限责任公司 Methods of treatment of cancer by continuous infusion of coenzyme q10
EP3967303A1 (en) 2014-04-08 2022-03-16 The Methodist Hospital Inos-inhibitory compositions and their use as breast cancer therapeutics

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3592836A (en) * 1966-12-23 1971-07-13 Bayer Ag Aryloxycarbonyl fluorides and amino acids and their production
US3796723A (en) * 1970-10-30 1974-03-12 Hoffmann La Roche Cyclodopa derivatives
GB1365702A (en) * 1970-12-09 1974-09-04 Aldrich Chem Co Inc Di-substituted beta-phenethylcarbamic acid esters
DE2424540A1 (en) * 1973-05-23 1974-12-12 Simes ERGOLINCARBAMATE
DE2448257A1 (en) * 1974-10-10 1976-04-22 Troponwerke Dinklage & Co Vasodilatory 7-thioureidocoumarin derivs. - specif. 3-(2-Aminoethyl)-4-methyl-7-thioureido-coumarin derivs. prepd. by reacting 7-amino cpds. with thiophosgene and amines
US4115539A (en) * 1976-05-17 1978-09-19 Union Carbide Corporation Analytical or clinical derivatives, tagged derivatives and methods of analysis using such derivatives
EP0584552A2 (en) * 1992-07-26 1994-03-02 Yeda Research And Development Company, Ltd. Chlorophyll and bacteriochlorophyll derivatives, their preparation and pharmaceutical compositions comprising them
EP0604278A1 (en) * 1992-12-18 1994-06-29 L'oreal Indoline derivatives and dye compositions for keratinic fibres
JPH0782280A (en) * 1993-06-30 1995-03-28 Kanebo Ltd New prodrug and its production
WO1995009841A1 (en) * 1993-10-07 1995-04-13 British Biotech Pharmaceuticals Limited Hydroxamic acid derivatives as inhibitors of cytokine production

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4812590A (en) * 1987-06-25 1989-03-14 Merck & Co., Inc. Carbamates of 4-hydroxyanisole as prodrugs for chemotherapy of melanoma
JP3469580B2 (en) * 1993-10-01 2003-11-25 帝国臓器製薬株式会社 New peptide derivatives
CA2155448A1 (en) * 1994-08-11 1996-02-12 Katerina Leftheris Inhibitors of farnesyl protein transferase

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3592836A (en) * 1966-12-23 1971-07-13 Bayer Ag Aryloxycarbonyl fluorides and amino acids and their production
US3796723A (en) * 1970-10-30 1974-03-12 Hoffmann La Roche Cyclodopa derivatives
GB1365702A (en) * 1970-12-09 1974-09-04 Aldrich Chem Co Inc Di-substituted beta-phenethylcarbamic acid esters
DE2424540A1 (en) * 1973-05-23 1974-12-12 Simes ERGOLINCARBAMATE
DE2448257A1 (en) * 1974-10-10 1976-04-22 Troponwerke Dinklage & Co Vasodilatory 7-thioureidocoumarin derivs. - specif. 3-(2-Aminoethyl)-4-methyl-7-thioureido-coumarin derivs. prepd. by reacting 7-amino cpds. with thiophosgene and amines
US4115539A (en) * 1976-05-17 1978-09-19 Union Carbide Corporation Analytical or clinical derivatives, tagged derivatives and methods of analysis using such derivatives
EP0584552A2 (en) * 1992-07-26 1994-03-02 Yeda Research And Development Company, Ltd. Chlorophyll and bacteriochlorophyll derivatives, their preparation and pharmaceutical compositions comprising them
EP0604278A1 (en) * 1992-12-18 1994-06-29 L'oreal Indoline derivatives and dye compositions for keratinic fibres
JPH0782280A (en) * 1993-06-30 1995-03-28 Kanebo Ltd New prodrug and its production
WO1995009841A1 (en) * 1993-10-07 1995-04-13 British Biotech Pharmaceuticals Limited Hydroxamic acid derivatives as inhibitors of cytokine production

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
ACTA POL. PHARM. (APPHAX,00016837);91; VOL.48 (3-4); PP.13-16, SCH. MED.;DEP. FUNDAM. CHEM.; LUBILN; 20081; POL. (PL) *
BURKE T R ET AL: "HYDROXYLATED AROMATIC INHIBITORS OF HIV-1 INTEGRASE", JOURNAL OF MEDICINAL CHEMISTRY, vol. 38, no. 21, 13 October 1995 (1995-10-13), pages 4171 - 4178, XP000569362 *
CHEMICAL ABSTRACTS, vol. 084, no. 3, 19 January 1976, Columbus, Ohio, US; abstract no. 012419, SIDORIK O A ET AL: "Antineoplastic properties of 2-phenazinylthioureidotyrosine" XP002062471 *
CHEMICAL ABSTRACTS, vol. 097, no. 8, 23 August 1982, Columbus, Ohio, US; abstract no. 065714, MANCHEVA I ET AL: "Possible amino acid analysis of peptide hydrolysates" XP002062473 *
CHEMICAL ABSTRACTS, vol. 118, no. 20, 17 May 1993, Columbus, Ohio, US; abstract no. 204428, PYRA E ET AL: "Chromatographic separation of some monoamines in the form of 4-N,N-dibutylaminoazobenzene-4'-thiocarbamoyl (DBABTC) derivatives" XP002062472 *
COOKSEY ET AL.: "Tyrosinase-mediated cytotoxicity of ...", QUANT. STRUCT.-ACT. RELAT., vol. 15, 1996, pages 498 - 503, XP002062470 *
DATABASE WPI Section Ch Week 9521, Derwent World Patents Index; Class B02, AN 95-158980, XP002062474 *
DOKL. BOLG. AKAD. NAUK (DBANAD,03668681);81; VOL.34 (11); PP.1525-8, HIGHER INST. CHEM.-TECHNOL.;DEP. ORG. CHEM.; SOFIA; 1156; BULG. (BG) *
HONG C I ET AL: "Synthesis and biological activity of analogs of naturally occurring 6-ureidopurines and their nucleosides", J. MED. CHEM. (JMCMAR);73; VOL.16 (2); PP.139-47, ROSWELL PARK MEM. INST.;GEN. CLIN. RES. CENT.; BUFFALO; N. Y., XP002062467 *
MIKROBIOL. ZH. (KIEV) (MZUKAV);75; VOL.37 (4); PP.500-1, INST. PROBL. ONKOL.;KIEV; USSR *
PANIGRAHI ET AL.: "Toward a mechanism-based fluorescent assay for ...", J.AM.CHEM.SOC., vol. 118, no. 48, 1996, pages 12004 - 12011, XP002062468 *
ROBBINS ET AL.: "Forskolin carbamates: Binding and activation ...", J.MED.CHEM., vol. 39, 1996, pages 2745 - 2752, XP002062469 *
RODRIGUEZ J ET AL: "THE STRUCTURES AND STEREOCHEMISTRY OF CYTOTOXIC SESQUITERPENE QUINONES FROM DACTYLOSPONGIA ELEGANS", TETRAHEDRON, vol. 48, no. 32, August 1992 (1992-08-01), pages 6667 - 6680, XP000615298 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002008174A1 (en) * 2000-07-26 2002-01-31 Patrick Anthony Riley Phenylethylamine derivatives and their use in the treatment of melanoma
US7183319B2 (en) * 2000-07-26 2007-02-27 Patrick Anthony Riley Phenylethylamine derivatives and their use in the treatment of melanoma

Also Published As

Publication number Publication date
DE69734670D1 (en) 2005-12-22
EP0944583A1 (en) 1999-09-29
GB9625895D0 (en) 1997-01-29
AU7846998A (en) 1998-07-03
DE69734670T2 (en) 2006-06-29
US6573284B1 (en) 2003-06-03
ATE309980T1 (en) 2005-12-15
AU748957B2 (en) 2002-06-13
EP0944583B1 (en) 2005-11-16

Similar Documents

Publication Publication Date Title
EP0944583B1 (en) Novel compounds useful as therapeutic agents and assay reagents
CA2669503C (en) Compounds and methods for thiol-containing compound efflux and cancer treatment
Blass et al. Dipyridamole: a potent stimulator of prostacyclin (PGI2) biosynthesis.
Montine et al. Neurotoxicity of endogenous cysteinylcatechols
US20090005437A1 (en) Alpha-Ketoglutarates and Their Use as Therapeutic Agents
EP2802572B1 (en) Halofuginol derivatives and their use in cosmetic and pharmaceutical compositions
UŽGIRIS et al. Stereoselective inhibition of cholesterol side chain cleavage by enantiomers of aminoglutethimide
Goldsborough et al. Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin
US20180265444A1 (en) Small molecule stimulators of steroid receptor coactivator proteins and their use in the treatment of cancer
CN111918864A (en) Prodrug compounds activated by AKR1C3 and their use to treat hyperproliferative disorders
Vaillant et al. Effectors of the mammalian plasma membrane NADH-oxidoreductase system. Short-chain ubiquinone analogues as potent stimulators
Zhang et al. Discovery of small molecules simultaneously targeting NAD (P) H: quinone oxidoreductase 1 and nicotinamide phosphoribosyltransferase: treatment of drug-resistant non-small-cell lung cancer
Kumar et al. Alkyne–azide cycloaddition analogues of dehydrozingerone as potential anti-prostate cancer inhibitors via the PI3K/Akt/NF-kB pathway
TW201302701A (en) Targeting human thymidylate kinase induces DNA repair toxicity in malignant tumor cells
JPH10503921A (en) NADH oxidase as a target in diagnosis and therapy
US11591301B2 (en) Indoleamine-2,3-dioxygenase inhibitor, preparation method therefor and use thereof
EP0210140B1 (en) Inhibitors of benzylaminoxidases, selective with respect to other aminoxidases
Wang et al. Antisense anti-MDM2 mixed-backbone oligonucleotides enhance therapeutic efficacy of topoisomerase I inhibitor irinotecan in nude mice bearing human cancer xenografts: in vivo activity and mechanisms
RU2352335C2 (en) Highly specific antitumoral pharmacological medicinal system, synthesis of medical product and method of modelling of medical product
Karakaya et al. Kojic acid derivatives as potential anticancer agents: Synthesis and cytotoxic evaluation on A375 human malignant melanoma cells
Kim et al. Synthesis of 6-chloroisoquinoline-5, 8-diones and pyrido [3, 4-b] phenazine-5, 12-diones and evaluation of their cytotoxicity and DNA topoisomerase II inhibitory activity
US20080064705A1 (en) Theophylline-based nitophenylpiperazine derivatives for enhancing aortic smooth muscle relaxation
JP2005330265A (en) New compound and their medical use
HU229160B1 (en) Aminoderivatives of biotin and their conjugates with macrocyclic chelating agents
US4880821A (en) α-nitroalkylnitrobenzenesulfonamides

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 09319866

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1997949046

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 78469/98

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 1997949046

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 78469/98

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1997949046

Country of ref document: EP